We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded, prescription and OTC products as well as infant nutritionals. We discontinued trade in Venezuela in the 2016 financial year. Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semi-solids and liquids.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Spanish Latin American private pharmaceutical sector was valued by IMS at USD23,1 billion for the year to 30 June 2017
- The Brazilian private pharmaceutical sector was valued by IMS at USD28,4 billion for the year to 30 June 2017 and Aspen is ranked 54th in this sector.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||0,8||0,7||44|
|Other Commercial Pharmaceutical Brands||1,2||1,1||6|
* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.